Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 7/15/04  and contains information from public web pages.

Dr. John Giannios

Wrong Dr. John Giannios?
 
Background

Employment History

  • Head of Radiotherapeutic Cancer Research
    IASO Hospital

Education

  • MD
6 Total References
Web References
Genomics and Proteomics - Experimental Procedure Combining Three Different Treatments Shows Promise in Cancer Therapy 7/15/04
www.genpromag.com, 15 July 2004 [cached]
But that could change due to a new, experimental procedure to kill metastatic breast cancer cells presented by John Giannios, MD, head of radiotherapeutic cancer research, IASO Hospital, Athens, Greece, at the 18th Annual Meeting of the European Association of Cancer Research in Innsbruck, Austria, on July 6, 2004.
Giannios's team looked for overexpression of known oncogenes in advanced breast cancer tumor tissue.They found overexpression of the oncogenes bcl-2, HER-2, Raf-1 and cdc25c, but also observed overexpression of DNMT1.DNMT1, a DNA methyltransferase, is involved in DNA replication during cell division, and is implicated in cancer development.The team also observed methylation of BRCA1 promoter, specifically implicated in the development of breast cancer tumors.
"What I have done is molecular targeted therapy circumventing chemoresistant and radioresistant mechanisms," says Giannios.Dubbed "chemoradioimmunotherapy," the technique combines chemotherapy, radiation therapy, and immunotherapy.The chemotherapy aspect involved vinorelbine-tartrate.The radiotherapy aspect was the use of high energy radioisotopes.And the immunotherapy component consisted of attaching an HER-2 specific antibody to the radioisotopes, as well as the inclusion of a 21-nucleotide double-stranded siRNA (small interfering RNA) created against DNMT1.Giannios's team hoped the treatment regimen would target the tumor cells by blocking the molecular mechanisms that protect the cells from conventional treatment.
"I am very optimistic about the results," says Giannios.Within 24 hours of treatment there was evidence that the treated tumor cells were dying at a significantly higher rate than in the untreated control cells."Apoptosis was confirmed by the detection of activation of caspase-3-9, an enzyme involved in apoptosis, inhibition of DNA synthesis and metabolic activity in the tumor cells and the formation of apoptotic bodies.These apoptotic bodies were seen to be phagocytosed (absorbed) by adjacent tumor cells, which resulted in the subsequent apoptosis of the tumor cells through a "bystander" killing effect."
"What we hope to achieve is that this is going to circumvent conventional treatment and make treatment more specific.It's not like a blockbuster policy, like conventional chemotherapy," says Giannios.
Chemoradioimmunotherapy for advanced breast cancer: hope for the future?
www.eurekalert.org, 6 July 2004 [cached]
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr. John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital, Athens, Greece at the 18th Annual Meeting of the European Association of Cancer Research today (Tuesday 6 July 2004).
...
According to Dr. Giannios, "This technique will be very applicable in a clinical setting where treatment difficulties will be limited because, as a tailored and targeted anti-cancer treatment, the treatment will reduce systemic toxicity whilst enhancing the therapeutic index.""Introducing the radiation by linking the radioisotopes to the anti-HER-2 antibody is more efficient than conventional external beam radiotherapy because the radiation is targeted specifically to those breast cancer cells that over-express HER-2/neu, leaving normal cells unaffected and thereby reducing system toxicity", he added.
"These results open the possibility of combining targeted immunotherapy with chemotherapy and radiation therapy to successfully kill metastatic tumour cells", said Dr. Giannios.
A successful, and novel, technique to ...
www.newzsnap.com, 12 Dec 2003 [cached]
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr. John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital, Athens, Greece at the 18th Annual Meeting of...
Vidyya Medical News Service   - Today in Vidyya   
www.vidyya.com, 7 July 2004 [cached]
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr. John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital, Athens, Greece at the 18th Annual Meeting of the European Association of Cancer Research on 6 July 2004.
...
According to Dr. Giannios, "This technique will be very applicable in a clinical setting where treatment difficulties will be limited because, as a tailored and targeted anti-cancer treatment, the treatment will reduce systemic toxicity whilst enhancing the therapeutic index.""Introducing the radiation by linking the radioisotopes to the anti-HER-2 antibody is more efficient than conventional external beam radiotherapy because the radiation is targeted specifically to those breast cancer cells that over-express HER-2/neu, leaving normal cells unaffected and thereby reducing system toxicity", he added.
"These results open the possibility of combining targeted immunotherapy with chemotherapy and radiation therapy to successfully kill metastatic tumour cells", said Dr. Giannios.
Chemoradioimmunotherapy as Future Treatment for Advanced Breast Cancer :: Cure Breast Cancer :: Fund the Fight : Find the Cure
www.curebreastcancer.org, 6 May 2004 [cached]
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr. John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital, Athens, Greece at the 18th Annual Meeting of the European Association of Cancer Research.
...
"These results open the possibility of combining targeted immunotherapy with chemotherapy and radiation therapy to successfully kill metastatic tumor cells", said Giannios.
Other People with the name "Giannios":
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304